Fubotv earnings beat by $0.10, revenue topped estimates
Enliven Therapeutics, Inc. (NASDAQ:ELVN), a $1.27 billion market cap biotech company whose stock has surged 10% in the past week, saw its President and CEO Samuel Kintz sell a total of 12,500 shares of common stock on June 17, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The sales, totaling $277,292, were executed in multiple transactions at prices ranging from $21.5935 to $22.9964.
Specifically, Kintz sold 10,502 shares at a weighted average price of $22.0757, and 1,998 shares at a weighted average price of $22.7494.
The shares are held by The Kintz & Egan Trust Dated March 30, 2019, for which Kintz serves as trustee. The sales were executed pursuant to a Rule 10b5-1 trading plan adopted by Kintz on November 15, 2024. Following the transactions, Kintz beneficially owns 952,892 shares of Enliven Therapeutics.
In other recent news, Enliven Therapeutics has reported positive data from its Phase 1 ENABLE trial for its chronic myeloid leukemia (CML) treatment, ELVN-001, showcasing a 47% cumulative major molecular response rate by 24 weeks. This data was presented at the European Hematology Association Congress, emphasizing the drug’s favorable safety profile and its potential for once-daily dosing. In parallel, Enliven Therapeutics has priced a $200 million public offering of common stock and pre-funded warrants, with Jefferies, Goldman Sachs & Co (NYSE:GS). LLC, TD Cowen, and Mizuho (NYSE:MFG) serving as joint book-running managers. This offering is expected to close soon, subject to customary conditions.
Additionally, Goldman Sachs has initiated coverage on Enliven Therapeutics with a Buy rating, highlighting the promising data for ELVN-001 compared to Novartis (SIX:NOVN)’ Scemblix. Mizuho Securities has also raised the price target for Enliven Therapeutics to $41, maintaining an Outperform rating. Analyst Salim Syed from Mizuho praised the company’s validated science and its positioning in the CML treatment market, which has a significant total addressable market. These developments reflect Enliven Therapeutics’ ongoing efforts to advance its clinical programs and secure funding for future initiatives.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.